Related Experiment Video
Updated: Jul 12, 2026

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies
Yibin Cai1, Jiayin Li2,3, Shenyu Chen4
1Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
None:
Liver fibrosis is a dynamic pathological process characterized by excessive extracellular matrix (ECM) deposition, primarily driven by the activation of hepatic stellate cells (HSCs). Recent advances in liver fibrosis research have identified critical pathways, such as oxidative stress, inflammation and transforming growth factor-β (TGF-β) signaling, which drive disease progression. Concurrently, innovative drug delivery systems (e.g., liposomes, micelles and nanocrystals) have emerged to enhance therapeutic efficacy and targeting. These systems enable precise delivery of antifibrotic agents to HSCs or fibrotic tissues, minimizing off-target effects and improving pharmacokinetic profiles. This review summarizes current understanding of liver fibrosis pathogenesis and recent advances in drug delivery strategies, highlighting clinical transformation opportunities and future research directions. Combining molecular insights with advanced delivery technologies represents a promising avenue for developing effective antifibrotic therapies.
Related Concept Videos
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
